Clinical Guides
Fungal Nail Infection (Onychomycosis)
An India-adapted clinical guide to confirming suspected onychomycosis, separating its mimics, selecting site- and organism-appropriate treatment, and reducing medicine-related harm and recurrence.
MedNext Academy | 14 min read
Fungal Nail Infection (Onychomycosis)
An India-adapted clinical guide to confirming suspected onychomycosis, separating its mimics, selecting site- and organism-appropriate treatment, and reducing medicine-related harm and recurrence.
Summary
Onychomycosis is fungal infection of the nail unit caused most often by dermatophytes, but yeasts and non-dermatophyte moulds can be responsible. Typical changes include distal or lateral onycholysis, yellow-white discoloration, subungual debris, thickening and crumbling. Appearance alone is unreliable because trauma, psoriasis, lichen planus, eczema, bacterial colonisation and tumours can look similar. The central quality rule is therefore to obtain mycological confirmation before exposing a patient to systemic antifungal treatment. Direct microscopy, culture, histopathology with a fungal stain or an appropriately validated molecular test can contribute, with method choice guided by availability and the need to identify an organism. A negative result may reflect sampling error or previous treatment and should be interpreted rather than automatically overruled.
Management depends on the affected digit, proportion of nail involved, matrix disease, number of nails, organism, nail thickness, symptoms, comorbidity, interactions, pregnancy status, cost and patient preference. Limited distal disease without matrix involvement may be suitable for prolonged topical therapy and nail care; extensive, matrix, proximal, multiple-nail or dermatophytoma disease often requires clinician-considered systemic treatment. Oral therapy can cause important hepatic and drug-interaction harms and must follow current local product information and assessment. Improvement is slow because clear nail must grow out; discolouration immediately after a course does not prove failure. Treat coexisting tinea pedis, address footwear and moisture, and plan follow-up. Diabetes, poor circulation or immunosuppression lowers the threshold for careful foot assessment and specialist input. This awaiting-review guide is educational, not a prescription. [ONY-1]
How Common Is It?
Fungal nail infection is common in adult dermatology and primary care, especially in toenails, but there is no single prevalence figure that should be applied to all of India. Estimates vary with climate, age, occupation, diagnostic method, whether clinically suspected or laboratory-confirmed disease is counted, and the population studied. A survey of people with diabetes, athletes, miners or dermatology-clinic attendees will not represent the general population. Studies also differ on whether Candida and non-dermatophyte mould isolates indicate true nail infection or contamination. Any local figure should therefore name the setting, definition and confirmation method.
Frequency rises with increasing age, repeated nail trauma, occlusive footwear, tinea pedis, peripheral vascular disease, diabetes and immunosuppression. Toenails grow more slowly and experience more trauma than fingernails, which helps explain their greater burden and slower apparent recovery. Infection is often dismissed as cosmetic, yet thick, painful or distorted nails can impair walking, footwear, manual work and self-care. A damaged nail and surrounding skin may add risk in a neuropathic or ischaemic diabetic foot, although onychomycosis alone does not establish an ulcer or bacterial infection. India adds wide variation in humidity, footwear, barefoot exposure, crowded living, access to laboratory testing and medicine affordability. Repeated empirical antifungals can be costly and obscure the diagnosis. Clinicians should distinguish suspected from confirmed onychomycosis in documentation and should not inflate public-health certainty where Indian representative data are absent. [ONY-2]
Risk Factors
Local risk factors include tinea pedis, repeated microtrauma, tight or occlusive footwear, sweaty feet, communal wet surfaces, nail damage, slow growth and difficulty trimming thick nails. Athletes, manual workers and people whose feet remain wet for long periods may have greater exposure, but occupation alone does not diagnose infection. A family or household pattern may reflect shared susceptibility, exposure or footwear rather than inevitable transmission. Toenail deformity from an old injury can both mimic infection and create a nail environment vulnerable to secondary fungal invasion. Psoriasis and other inflammatory nail disorders may coexist with fungus, so identifying one does not always explain the entire dystrophy.
Systemic susceptibility includes older age, diabetes, peripheral arterial disease, neuropathy, immunosuppression, HIV, transplantation and some cancer treatments. Ask about recurrent skin infection, poor wound healing and medicines that alter immunity. In diabetes, assess glycaemic context, sensation, pulses, skin breaks, footwear and ability to inspect the feet; a sharp thick nail can cause trauma even if fungal treatment is deferred. Proximal subungual disease, rapid progression or unusual organisms can warrant evaluation for immune compromise according to the wider history. Previous partial treatment, poor adherence, untreated tinea pedis, contaminated footwear and an inaccurately identified mould can contribute to apparent recurrence. Antifungal resistance is a possible but not default explanation; poor sampling, wrong diagnosis, insufficient penetration, slow nail growth and reinfection are often more plausible. Pregnancy, liver disease, heart failure, kidney impairment and polypharmacy are not causes of onychomycosis, but they materially alter the safety of treatment choices. [ONY-3]
Diagnosis
History
Record which nails are affected, sequence, duration, pain, walking or work limitation, trauma, footwear, wet exposure, tinea pedis, psoriasis and prior tests or treatment. Ask about diabetes, neuropathy, circulation, immune status, pregnancy or breastfeeding, liver and kidney disease, heart failure, alcohol use, allergies and every prescribed, over-the-counter, traditional or supplement product. Clarify whether appearance changed after empirical antifungals and whether family members have skin or nail disease.
Examination
Inspect all fingernails and toenails, surrounding folds, interdigital spaces, soles, palms and relevant skin. Describe distribution and pattern: distal lateral subungual, superficial white, proximal subungual, endonyx or total dystrophic. Estimate percentage involvement, matrix extension, subungual thickness and possible dermatophytoma. Look for pitting, oil-drop change, periungual inflammation, bacterial pigment, longitudinal melanonychia, ulceration and a solitary destructive lesion. In a diabetic or high-risk foot, assess pulses, sensation, deformity, pressure injury and infection.
Investigations
Confirm fungus before systemic therapy. Obtain an adequate sample from the most proximal active diseased area after cleaning: subungual debris or nail clipping according to phenotype, not merely the crumbly free edge. Potassium hydroxide microscopy can show fungal elements quickly; culture may identify genus or species and guide unusual cases but is slower and can be falsely negative or contaminated. Periodic acid-Schiff histology of clippings is sensitive for invasion but may not identify the organism. Molecular tests can be useful where validated and affordable. Repeat correctly targeted sampling or seek dermatology/mycology input when suspicion remains high after a negative result. [ONY-1]
Differential Diagnosis
Traumatic onycholysis and onychodystrophy are common mimics, particularly when one repeatedly impacted great toenail is affected. Nail psoriasis may produce pitting, oil-drop or salmon-patch change, subungual hyperkeratosis and onycholysis; skin or joint findings help but can be absent. Lichen planus can cause thinning, longitudinal ridging, splitting and pterygium with permanent scarring. Chronic dermatitis, alopecia areata, pachyonychia, age-related thickening and medication-related nail change broaden the differential. Chronic paronychia with Candida colonisation is not automatically Candida invasion of the nail plate, and a positive culture must fit the phenotype.
Green or dark pigment can reflect bacterial colonisation, blood, exogenous stain or melanin. A new or changing longitudinal pigmented band, periungual pigment, nail-plate destruction, bleeding mass or persistent single-nail dystrophy raises concern for nail-unit melanoma or squamous cell carcinoma and needs urgent specialist assessment rather than repeated antifungals. Painful focal lesions may represent glomus tumour, wart or other nail-unit pathology. Yellow nail syndrome and systemic disease produce different multi-nail patterns. Non-dermatophyte moulds are difficult because environmental contamination is common; repeated isolation, compatible microscopy or histology and clinical correlation may be required before assigning causality. Mixed infection is possible. Failure of terbinafine is not proof of mould infection or resistance. A diagnostic label should state the evidence: clinically suspected, microscopy-positive, culture-confirmed or histology-supported, along with organism where known. This precision prevents prolonged treatment of psoriasis, trauma or malignancy as fungus. [ONY-1]
Management
First decide whether treatment is necessary now. Mild asymptomatic disease may be observed with nail care after discussing progression, transmission uncertainty and risk, whereas pain, functional impairment, spreading disease or a high-risk foot favours active management. Correct tinea pedis, reduce moisture and trauma, keep nails safely trimmed, and debride excessive thickness when skilled care is available. Do not share clippers, and clean instruments between users. Mechanical or chemical approaches can reduce load or improve penetration but are usually adjuncts rather than reliable stand-alone cures. Complete nail avulsion is not routine and can create wound risk, especially with diabetes or poor circulation.
Topical lacquer or solution is most rational for limited superficial or distal disease without matrix involvement, when systemic treatment is unsuitable, or as part of selected combination or recurrence-prevention strategies. Adherence is difficult because treatment lasts for months and requires correct preparation and application. Systemic therapy is more effective for extensive dermatophyte disease, multiple nails, matrix involvement, marked thickening, proximal disease or dermatophytoma, but only after confirmation and safety assessment. Nail Society of India guidance generally favours terbinafine for dermatophyte disease and itraconazole for selected non-dermatophyte or Candida patterns, with organism, contraindications and interactions determining the actual choice. Combination topical-systemic therapy is not automatically superior for every patient. Laser, photodynamic, device and home remedies have variable or limited evidence; visible clearing without mycological assessment is not necessarily cure. Agree whether the goal is symptom relief, mycological cure, clinical clear growth or prevention of diabetic-foot trauma, then schedule follow-up around nail growth rather than expecting rapid normalization. [ONY-3]
Prescribing Information
Systemic antifungals require a confirmed indication, medication reconciliation and current Indian product information. Terbinafine can cause gastrointestinal symptoms, rash, headache, taste or smell disturbance and uncommon serious hepatic or severe cutaneous reactions. Azoles, especially itraconazole, create clinically important cytochrome-mediated interactions and require caution or avoidance in heart failure and liver disease. The precise interaction depends on the co-medication and formulation; check anticoagulants, cardiovascular drugs, lipid-lowering medicines, antiepileptics, immunosuppressants and other agents rather than relying on memory. Baseline liver assessment is recommended in Indian nail guidance for oral treatment, with subsequent monitoring driven by agent, duration, symptoms, comorbidity and local label. Stop-and-assess symptoms include jaundice, dark urine, persistent nausea, severe fatigue, pale stool, widespread rash, blistering or mucosal lesions.
Do not reproduce a one-size dosing schedule without organism, site, age, liver and kidney context. Fingernails and toenails have different treatment and regrowth times, and pulse versus continuous regimens are not interchangeable across drugs. Oral antifungal treatment is generally deferred in pregnancy because onychomycosis is slowly progressive and fetal safety evidence is limited; breastfeeding decisions also need current product data. Children, older adults, transplant recipients and people with HIV, diabetes, cardiac disease or polypharmacy warrant tailored review. Topical products have fewer systemic interactions but lower complete-cure rates and still require counselling about application, local reactions, availability and cost. Avoid oral ketoconazole for routine nail infection because systemic harm outweighs its role. Do not combine products or repeat courses empirically after failure. Confirm adherence and diagnosis, allow growth time, review susceptibility questions with mycology expertise, and never start or stop prescription antifungals from this page alone. [ONY-3]
When to Refer
Refer urgently for suspected nail-unit melanoma or squamous cell carcinoma: a new or evolving pigmented band with concerning features, pigment extending onto surrounding skin, unexplained bleeding, ulceration, a mass, progressive plate destruction or persistent solitary dystrophy without a coherent benign explanation. Acute spreading cellulitis, fever, a diabetic-foot wound, ischaemic features, rapidly progressive tissue damage or severe immunosuppression with invasive infection concern needs prompt medical assessment rather than routine nail treatment. A painful nail with drainage may require evaluation for bacterial infection or an ingrowing nail in addition to possible fungus.
Refer routinely to dermatology when diagnosis remains uncertain after properly collected testing, samples repeatedly disagree, a non-dermatophyte mould or mixed infection is suspected, many nails or the matrix are involved, disease relapses despite confirmed appropriate therapy, or psoriasis, lichen planus and fungus may coexist. Mycology advice is valuable for unusual isolates and possible resistance. High-risk patients with diabetes, neuropathy, peripheral arterial disease, transplantation, HIV, chemotherapy or inability to perform foot care may need coordinated dermatology, physician, podiatry or surgical services according to local resources. Pregnancy with severe symptomatic disease and significant liver, kidney, cardiac or interaction complexity also justify specialist planning before systemic treatment. The referral should state site and pattern, percentage and matrix involvement, photographs where consented, sampling method and results, organism, prior treatments and adherence, liver or renal data, medicines, comorbidity, pregnancy status, neurovascular foot findings and the clinical question. Do not promise a podiatry or mycology service without confirming local availability. [ONY-4]
Red Flags
The most important diagnostic red flag is a solitary, progressive nail abnormality that does not behave like ordinary distal fungal disease. Longitudinal pigmentation that is widening or irregular, extension onto the proximal or lateral fold, nail destruction, unexplained bleeding, ulceration, a subungual mass or persistent pain requires assessment for melanoma, squamous malignancy or another tumour. Do not repeatedly sample only for fungus while a lesion evolves. Black colour can be blood, organism, stain or melanin; history and dermoscopic or biopsy expertise may be needed. Severe periungual inflammation, pus, lymphangitis, fever or rapidly spreading erythema suggests bacterial complication.
Foot red flags include ulceration, necrosis, rest pain, absent pulses, acute colour or temperature change, deep infection, loss of protective sensation with injury, and inability to bear weight. These are especially important in diabetes and immunosuppression and should not wait for a fungal culture. Medicine red flags after an oral antifungal include jaundice, dark urine, marked anorexia, persistent vomiting, severe fatigue, widespread rash, blistering, facial swelling, breathing difficulty or mucosal involvement. A major interaction, pregnancy discovered during therapy or new heart-failure symptoms warrants prompt prescriber review. Proximal subungual disease, extensive unusual infection or rapid spread may be a clue to immune compromise, though it is not diagnostic by itself. Repeated negative tests are a reason to revisit sampling and alternatives, not to escalate treatment indefinitely. Document neurovascular findings, systemic symptoms, drug exposure and the exact reason for emergency or urgent referral. [ONY-4]
Indian Clinical Context
Indian practice spans advanced molecular laboratories and settings where only microscopy or no immediate mycology is available. The safety standard remains confirmation before systemic therapy; when testing is inaccessible, it is safer to improve sampling access, use conservative nail care or refer than to expose repeated unconfirmed dystrophy to oral antifungals. Potassium hydroxide microscopy can be a pragmatic first test when performed by trained staff, while culture or histology becomes important for atypical, failed or mould-suspected disease. Explain that a result may take time and that a thick nail will not look normal immediately. Costs of laboratory tests, prolonged topical products, monitoring and travel should be discussed before a plan is chosen.
The Nail Society of India recommendations provide locally relevant pharmacologic and special-population guidance, including medicine availability, organism patterns and comorbidity. They remain professional recommendations rather than substitutes for an individual prescription, current CDSCO-approved product information or institutional policy. Humidity, occlusive occupational footwear and widespread tinea may favour reinfection, but advice must be feasible: drying feet, rotating breathable footwear when possible, treating skin infection, not sharing tools, and avoiding traumatic pedicures. Fixed-dose steroid-antifungal mixtures used for skin disease should not be applied indiscriminately around nails, and family members should not share oral antifungals. In diabetes, daily foot inspection and safe nail care matter as much as cosmetic clearance; people with poor vision, neuropathy or limited mobility may need assistance. Respect work demands, barefoot cultural practices and household constraints without blame. Evidence for Indian organism distribution, resistance and comparative effectiveness is incomplete and varies by region, so culture results and local specialist knowledge should outweigh broad claims. [ONY-3]
NMC Competency Mapping
Onychomycosis integrates NMC CBME learning across dermatology, microbiology, pharmacology, medicine, pathology, surgery, community medicine and professionalism. At Know level, learners should describe nail anatomy, major clinical patterns, common dermatophyte, yeast and mould causes, and the time required for normal nail growth. They should list important mimics and recognise that nail dystrophy is not synonymous with fungus. At Know How level, learners should justify confirmation before systemic therapy, choose a sample from the active diseased area, interpret microscopy, culture and histology limitations, and relate treatment choice to site, matrix involvement, organism, comorbidity and interactions.
At Show How level, a learner should inspect all nails and skin, describe rather than merely label the lesion, collect or demonstrate correct sampling, perform a high-risk foot screen, reconcile medicines, counsel about slow regrowth and communicate a follow-up plan. Simulation should test recognition of melanoma and diabetic-foot red flags, pregnancy counselling, liver-warning advice and response to a negative first specimen. At Perform level, examination, sampling and treatment occur only within supervision, institutional infection-control standards and prescribing scope. Learners must not initiate systemic antifungals independently because they recall a preferred drug. Competency assessment should reward diagnostic stewardship and avoidance of unnecessary antimicrobial exposure. Professional behaviours include consent for photography or clipping, confidential handling of HIV or immune-status information, non-judgmental enquiry about traditional products, affordable shared decisions and accurate recording of suspected versus laboratory-confirmed infection. A single guide supports learning but does not certify competence in dermoscopy, biopsy, mycology or diabetic-foot management. [ONY-5]
Key Exam Pearls for NEET PG
Onychomycosis should be confirmed before systemic treatment because only a proportion of dystrophic nails are fungal. A proximal active subungual sample is more useful than clipping only the distal free edge. Potassium hydroxide microscopy demonstrates fungal elements rapidly; culture can identify an organism but is slower and may be falsely negative or contaminated; periodic acid-Schiff staining can show invasion in nail clippings but usually does not speciate. Non-dermatophyte mould causation needs stronger clinicomycological correlation than a single environmental isolate. Distal lateral subungual disease is common; proximal subungual involvement should prompt attention to immune status and the wider differential.
Limited disease without matrix involvement can be considered for topical treatment, while extensive plate involvement, matrix disease, multiple nails, dermatophytoma or topical failure favours systemic assessment. For confirmed dermatophyte disease, Indian guidance generally favours terbinafine; azole choice may fit Candida or selected mould disease but interactions and cardiac or hepatic cautions matter. Do not select oral ketoconazole. Toenail treatment and visible recovery take longer than fingernail recovery because growth is slower. Persistent dystrophy soon after therapy does not prove microbiological failure; follow proximal clear growth and define clinical versus mycological cure. Always treat associated tinea pedis and address reinfection. In diabetes, examine pulses, sensation, ulcers and footwear rather than treating the nail in isolation. A changing pigmented band, periungual pigment, bleeding, a mass or solitary destructive nail is a tumour question, not another empirical antifungal course. Pregnancy generally favours deferral of systemic therapy and conservative or topical planning because the condition is slow and safety evidence is limited. [ONY-1]
Frequently Asked Questions
Why should a nail sample be tested before starting oral antifungal medicine?
Many fungal-looking nails are actually changed by trauma, psoriasis, lichen planus, eczema or a tumour. Oral antifungals require weeks or months of exposure and can cause liver injury or important drug interactions. Microscopy, culture, histology or a validated molecular test can support the diagnosis and sometimes identify the organism. A negative test is interpreted alongside sample quality and previous treatment; it may justify repeat proximal sampling, not automatic empirical tablets. Confirmation improves both safety and the chance that treatment matches the actual cause.
When is topical treatment reasonable and when might systemic treatment be considered?
Topical therapy is most reasonable for limited superficial or distal disease without matrix involvement, or when oral treatment is unsuitable. It requires correct preparation, long adherence and realistic expectations because complete cure rates are modest. Systemic treatment is more often considered for extensive disease, several nails, matrix or proximal involvement, marked thickening, dermatophytoma or failure of adequate topical therapy. The choice still requires laboratory confirmation, organism assessment, medication reconciliation and review of pregnancy, liver, kidney, cardiac and interaction risks.
How long does it take for an infected nail to look normal after treatment?
A successful antifungal course does not instantly remove damaged nail. Improvement appears as healthy proximal growth while old dystrophic plate moves outward, so fingernails take months and toenails often take considerably longer. Some residual deformity may persist after infection clears because trauma or another nail disorder caused permanent change. Follow-up should distinguish mycological cure from complete clinical clearing and should allow an appropriate growth interval. Early appearance alone should not trigger repeated oral courses without checking adherence, diagnosis, sampling and reinfection.
What makes fungal nail disease more urgent in someone with diabetes or immunosuppression?
The nail itself is usually slow-moving, but a thick or sharp nail can injure a foot with neuropathy, while poor circulation or immune suppression increases concern about wounds and secondary infection. Seek prompt care for ulceration, spreading redness, pus, fever, necrosis, rest pain, acute colour change or inability to bear weight. Assessment should include pulses, sensation, skin, footwear and glycaemic or immune context, not only the nail. Medicine choice also needs interaction and organ-function review. High-risk patients may require coordinated dermatology, physician and foot-care services.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic